Howard W Levine
Partner
Washington, D.C.

Biography
Howard W. Levine focuses his practice on complex
intellectual property litigation in the pharmaceuticaland biotechnology sectors. Howard has been leadcounsel in district court litigations throughout thecountry and in appeals before the U.S. Court of Appeals
for the Federal Circuit. Over the last 30 years, he has
represented companies on their most valuable mattersand has been at the forefront of legal developments inthis space, including precedent concerning the written
description requirement under 35 U.S.C. § 112. Howardis recognized across the market as a leader in theindustry, consistently ranked by LMG Life Sciences.
Howard represents clients from both thepharmaceutical and biotechnology industries on anarray of technologies. Notably, he was involved insuccessful litigation regarding the first biotechnology
product to be marketed, human insulin, among Eli Lilly,Genentech and the Regents of the University ofCalifornia. Howard also has extensive experience incases arising from the filing of Abbreviated New Drug
Applications (ANDAs). Some prominent products
Howard provided litigation counsel on include,
Humulin®, Humatrope®, Zantac®, Paxil®, Evista®,
Xigris®, Cymbalta®, Gemzar®, Differin®, Savella®,
Saphris®, Fetzima®, Bunavail® and Belbuca®.

Representative experience
Represented Allergan and Forest Laboratories inmultiple Hatch-Waxman litigations against defendants

Phone+1 202 637 6431

Fax+1 202 637 5910

Emailhoward.levine@hoganlovells.com

PracticesIntellectual Property
IP Litigation, Arbitration, andAlternative Dispute Resolution
PatentsIndustries
Life Sciences and Health Care

Education and admissions
Education
Juris Doctor, Georgetown University
Law Center, cum laude, 1993
Bachelor of Arts, Duke University,cum laude, 1990

seeking to prematurely launch generic versions ofSaphris® and Savella®.

Bar admissions andqualifications

Represented BDSI in Hatch-Waxman litigation against
Alvogen seeking to launch generic versions ofBelbuca® for the treatment of chronic pain, both at trial
and on appeal before the Federal Circuit.

District of Columbia

Represented DuPont de Nemours, Inc. (“DuPont”) in
multiple district court litigations and Federal Circuit
appeals concerning flexographic printing technology.

U.S. District Court, District ofColumbia
New York
U.S. Court of Appeals for the Federal
Circuit
U.S. Supreme Court
U.S. Patent & Trademark Office

Represented DuPont in post-trial proceedings andbefore the Federal Circuit concerning commercial
enzyme technology and the application of the written
description requirement of 35 U.S.C. § 112.
Represented Eli Lilly at trial and before the Federal
Circuit, including representing Lilly in the landmark
Ariad en banc rehearing concerning the written
description requirement of 35 U.S.C. § 112.
Represented Eli Lilly against defendants seeking toprematurely launch generic versions Cymbalta®, Lilly’s
blockbuster drug for the treatment of depression.
Represented Syngenta in multiple district court
litigations and before the Federal Circuit concerning
genetically engineered crops, including successfully
obtaining summary judgment on their behalf.

Latest thinking and events
News
Spotlight on the U.S.: Panelists discuss navigating
the IRA
Hogan Lovells Events
Hogan Lovells APAC Life Sciences and Health Care
Webinar Series - Spotlight on the U.S. - Session 2
Hogan Lovells Events
J.P. Morgan Healthcare Conference
Webinar
Select IP with Hogan Lovells | Webinar no. 22:
Recent developments, risks and risk mitigation inU.S. “Hatch-Waxman” patent litigation

Court admissions

Press releases
Hogan Lovells welcomes life sciences patent
litigation team to Washington, D.C. and Silicon
Valley offices